How to use and dosing macituximab/magenex

Margetuximab is administered as an intravenous infusion and administered by medical staff through a medical institution. According to the drug package insert, the recommended dose is 15 mg/kg as a 21-day infusion every 3 weeks, with treatment typically continued until disease progression or unacceptable toxicity. Throughout the medication cycle, infusion speed, infusion time, dose calculation and adverse reaction monitoring need to be strictly followed.

The first infusion usually takes a long time to ensure that the drug enters the circulation system stably in the body. The recommended initial infusion time is approximately 120 minutes, which helps reduce the risk of infusion-related reactions. Subsequent maintenance therapy infusion times can be shortened to at least 30 minutes, provided the patient has not experienced significant infusion reactions during previous courses.

Because margituximab is often used in combination with chemotherapy drugs, the order of treatment is also important. When chemotherapy and margetuximab are scheduled at the same time on the same day, it is generally recommended to complete chemotherapy first and then infuse margetuximab. This sequence has been explained in many overseas guidelines. The reason is that chemotherapy can first put pressure on tumor cells and then allow antibodies to exert an immune-dependent effect. The overall treatment sequence has a better synergistic effect.

During the entire treatment process, patients need to regularly monitor cardiac function, liver function, immune system status and infusion reactions. HER2-targeting antibody drugs may have an impact on heart function, so guidelines from many countries recommend regular echocardiography examinations to ensure that the heart's pumping ability is within a safe range. If cardiac function declines, you need to evaluate with your doctor whether to suspend treatment. In addition, patients are more likely to have mild infusion reactions during their first medication, so medical staff will observe before and during the initial infusion and decide whether pretreatment drugs are needed based on the situation.

Reference materials:https://www.margenza.com/